HRT and Fibroids: Can You Take Hormone Therapy Safely?

The HRT Index Editorial TeamIndependent women's health research

Last reviewed: August 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 6, 2026 · Last verified: August 6, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Find the right starting point before changing HRT

Find My HRT Path helps organize symptoms, treatment preference, safety history, budget, and state. It cannot assess unexplained bleeding, review imaging, or replace an in-person gynecology evaluation.

Find My HRT Path

The short answer

HRT and fibroids are not automatically incompatible. Fibroids are not listed as a contraindication in the six current US menopause-hormone labels we checked, and March 2026 clinical guidance says fibroids alone do not rule out HRT. The answer changes with bleeding, menopause stage, fibroid size and location, symptoms, and the progestogen plan.

That bleeding question matters more than everything else on this page. We'll get to it.

Best for you if: you have known fibroids, you want relief from menopause symptoms, and someone told you no without explaining what in your scan or history changed the answer.

Not enough for you if: you have new or unexplained bleeding after menopause — or bleeding outside the expected pattern of prescribed sequential HRT — a fibroid that has grown since menopause, a new pelvic lump, or new persistent pain or pressure. Those need an in-person assessment before a website or online intake form can settle the hormone question. Jump to the red-flags section.

Where to start, in one table

Your situation	The honest bottom line	Best first step
Known fibroids, no new bleeding, no new pain or pressure, and a scan report you can produce	Fibroids alone do not rule out HRT	An online menopause visit can be a reasonable place to start if the service can review records and arrange imaging when needed
Heavy or changing bleeding while you are still having periods	Fibroids may be part of it. They are rarely the whole story	Get assessed early; the exact route depends on bleeding severity and your wider risk history
New or unexplained bleeding after menopause, or bleeding outside an expected cyclic HRT pattern	Do not assume it is the fibroid. Do not assume it is the HRT	Prompt clinical evaluation
A fibroid that has grown after menopause, or a new pelvic lump	This cannot be sorted out by an online questionnaire	In-person gynecology first
Uterus fully removed	The fibroid question is usually closed	Estrogen-only may become the conversation; the operative report still matters

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Can you take HRT if you have fibroids?

Yes, in many cases. Having uterine fibroids does not automatically rule out menopausal hormone therapy. A March 2026 Women's Health Concern factsheet developed with the British Menopause Society's medical advisory council says fibroids are not a contraindication to receiving or continuing HRT, although HRT may reduce the amount of postmenopausal fibroid shrinkage. But "not a contraindication" is a floor, not a green light — bleeding, symptoms, menopause stage, fibroid size and location, and your wider health history still shape the decision.

Let's define the word, because everyone uses it and nobody explains it. A contraindication is a circumstance listed in a medicine's official prescribing information in which that product should not be used. It is not the same thing as a side effect, a warning, or a reason for individualized monitoring.

Fibroids were not on the contraindication list in any of the six current US menopause-hormone labels we reviewed for this page.

That is a fact about documents, not a promise about your body. We'll show you the documents in a minute.

Five things that change the answer

Have you had new or unexplained bleeding after menopause, or has an expected HRT bleeding pattern changed? This outranks everything else here.
Where is the fibroid? Submucosal fibroids — the ones projecting into the uterine cavity — behave differently from intramural and subserosal fibroids.
How big is it, and has it changed? The most reassuring recent study excluded submucosal fibroids and fibroids measuring 5 cm or more.
Which progestogen are you taking, and at what dose? Small trials repeatedly suggest that the progestogen plan can matter.
Do you still have a uterus? After a total hysterectomy, a different and usually simpler hormone conversation begins.

Does that sound like your situation? Do not walk into the next appointment with only the word fibroid. Find the starting point that fits your situation → About 90 seconds. No email needed.

Why you may have been told no

If you were refused hormone therapy as soon as the word fibroid appeared, you were given a general principle instead of a case-specific answer. The principle goes: fibroids respond to hormones, HRT contains estrogen, so estrogen is dangerous. It is not nonsense. It is incomplete — and it skips the questions that actually decide the answer.

Here is the logic you may have been handed:

Fibroids are hormone-sensitive. → HRT contains estrogen. → So HRT is off the table for you.

The first two statements are true. The conclusion still does not automatically follow, because that reasoning treats "hormone-sensitive" as if it means "any amount of hormone, in any form, at any dose, is a problem." That is not how the drug labels are written, and it is not what the mixed clinical research shows.

There is also a second problem. You are actually asking two different questions, and almost every page online mashes them into one.

Question 1: Will HRT grow the fibroids I already have? Question 2: Will HRT lead to a new fibroid diagnosis or make surgery more likely after menopause?

Different research answers those questions. Different answers come back. We have split them into separate sections, because collapsing them is how you end up frightened and no better informed.

You got a two-second answer to a twenty-minute question. Here is the twenty-minute version.

The fear usually comes out in three sentences

These are not testimonials and they are not medical evidence. They are the three thoughts this page is built to resolve:

She said no because of my fibroids, and that was the end of it.
I thought menopause would shrink them.
Am I feeding it?

Do fibroids shrink after menopause?

Most fibroids get smaller and quieter after menopause as ovarian estrogen and progesterone production falls. But "most" is not "all." The March 2026 Women's Health Concern factsheet says fibroids tend to shrink after menopause, while HRT can make that reduction less pronounced. Postmenopausal fibroids also still lead to diagnoses and surgery in a small minority of women.

The largest population study we found was the Million Women Study analysis: 610,604 postmenopausal women followed for an average of 11.4 years. The five-year rate of hospital admission with surgically confirmed fibroids fell steadily with age:

Group	5-year rate of surgically confirmed fibroids
Postmenopausal women aged 50–54	0.50% — about 1 in 200
Postmenopausal women aged 75–79	0.11% — about 1 in 900
Premenopausal women aged 50–54, for comparison	1.94% — about 1 in 50

Source: Sommer et al., European Journal of Epidemiology, 2015. These are age-specific population rates, not a personal forecast and not rates separated by HRT use.

Hold on to that 1-in-200 figure. It becomes important later, when we get to the scary statistic.

Why yours may not have shrunk

Adipose tissue contributes to estrogen production after menopause, and higher body mass index was associated with a higher rate of surgically confirmed fibroids in the Million Women Study. That association does not prove that losing weight will shrink an existing fibroid, and it does not turn body weight into a treatment plan.

Fibroids can also calcify rather than disappear. A calcified fibroid may remain obvious on a scan while staying clinically quiet. The image can look dramatic even when the fibroid is no longer causing the problem that brought you to the scan.

And if you waited out perimenopause because someone promised menopause would fix this, and it did not: you were given the average. You were not given the range.

Are fibroids a contraindication to HRT? What six US labels actually say

No — not in the six current US prescribing-information records we checked. Those records span oral estrogen, an oral estrogen-progestogen combination, estradiol patches, an injectable estrogen, and vaginal estradiol cream. In each one, fibroids were absent from Contraindications and appeared, when mentioned, in adverse-reaction reporting instead. This is an original label audit, not a claim that we reviewed every menopause product sold in America.

This is the part nobody else does, so let's be specific about what we did. We read the live DailyMed prescribing-information records as they appeared on August 6, 2026.

The labels use three different kinds of language:

Contraindications: circumstances in which the product should not be used.
Warnings and precautions: risks that require attention, selection, counseling, or monitoring.
Adverse reactions: events observed in trials or reported after approval. A report does not automatically prove the product caused the event.

The Fibroid Line Ledger

Verified against the current DailyMed records on August 6, 2026.

Product reviewed	Form	Fibroids listed under Contraindications?	Where fibroids appear instead
Activella (estradiol 1 mg/norethindrone acetate 0.5 mg)	Oral tablet	No	Clinical-trial table as "Uterine Fibroid" and postmarketing as "increase in size of uterine leiomyomata"
Estradiol tablets (current generic record)	Oral tablet	No	Adverse reactions: "increase in size of uterine leiomyomata"
Vivelle-Dot	Estradiol patch	No	Postmarketing adverse reactions: "increase in size of uterine leiomyomata"
CombiPatch	Estradiol/norethindrone acetate patch	No	Postmarketing adverse-reaction reporting includes uterine leiomyomata
Delestrogen	Estradiol valerate injection	No	Adverse reactions: "increase in size of uterine leiomyomata"
Estradiol Vaginal Cream 0.01% (current generic record)	Vaginal cream	No	Adverse reactions: "increase in size of uterine leiomyomata"; the label also says systemic absorption may occur

"Leiomyomata" is the medical word for fibroids. Same thing.

The ledger is useful because it separates three statements people often blur together:

Fibroids are not listed as a contraindication in these six records.
Fibroid enlargement has been reported as an adverse reaction on several estrogen-containing labels.
Neither statement tells us how an individual fibroid will respond to an individual regimen.

The one label with a comparison group

Activella's clinical-trial table reports "Uterine Fibroid" as an adverse event in three studies with comparison groups. That lets us see the event counts instead of reading an isolated warning line.

Trial in the Activella label	On Activella	Comparison group
12-month endometrial study	5% (n=295)	4% on estradiol alone (n=296)
3-month hot-flash study	0% (n=29)	0% on placebo (n=34)
2-year bone study	4% (n=47)	8% on placebo (n=48)

In the two-year trial, fibroid events were recorded twice as often in the placebo group as in the Activella group.

Now the guardrails, because this number gets misused fast. Those groups were tiny — 47 and 48 women. The table reports adverse events regardless of whether investigators thought the drug caused them. It does not say the fibroids were newly formed, growing, symptomatic, or surgically confirmed. This does not show that HRT protects against fibroids. It shows that the only randomized comparison inside the six labels did not produce a clean, one-directional signal.

Why the vaginal-cream line needs careful reading

The same fibroid-enlargement sentence appears in the prescribing information for estradiol vaginal cream 0.01%. That record also states that systemic absorption may occur. It should not be treated as proof that all low-dose vaginal estrogen products have zero systemic exposure, and it should not be used to pretend that every vaginal product has the same absorption profile.

Our document-level interpretation is narrower: the repeated wording across very different estrogen products looks like class-style adverse-reaction language rather than a measured product-specific fibroid rate. That is our reading of the labels, not an FDA conclusion.

What adverse-reaction reporting does and does not tell you

We'll argue against our own point here, because you deserve it.

Postmarketing reports are voluntary. The labels say their frequency cannot be reliably estimated and that causation cannot always be established. So "it is only in adverse reactions" is not proof that nothing happens. It means the event has been reported without a reliable rate or clean causal estimate.

A label is a regulatory document. It is not a treatment plan. "Not contraindicated" means the door is not locked. It does not mean walk through it without looking.

And there is a real difference between a clinician who says no after reading your scan and your history, and one who says no on hearing the word fibroid. We can help you tell those apart. We cannot overrule the first kind, and we will not try.

Regulatory update: On February 12, 2026, FDA announced approved boxed-warning changes for an initial group of six menopausal hormone therapy products and said 29 manufacturers had submitted proposed changes. Label records do not all update on the same day. This page therefore cites the live product record checked on August 6, 2026 rather than assuming a class-wide label has already changed.

Why do two FDA-approved fibroid drugs contain estrogen?

Oriahnn and Myfembree are both FDA-approved to manage heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Each regimen contains estradiol 1 mg and norethindrone acetate 0.5 mg as add-back therapy. That does not make them menopause HRT, and it does not mean ordinary HRT treats fibroids. It shows why context around a dose matters.

Read that again, because it reframes the whole fear.

	Activella (menopause HT)	Oriahnn (fibroid treatment)	Myfembree (fibroid treatment)
Estradiol	1 mg	1 mg in the morning capsule	1 mg once daily
Norethindrone acetate	0.5 mg	0.5 mg in the morning capsule	0.5 mg once daily
GnRH antagonist	None	Elagolix 300 mg in the morning plus 300 mg in the evening	Relugolix 40 mg once daily
FDA-approved use relevant here	Menopause vasomotor symptoms and other labeled menopause indications	Heavy menstrual bleeding associated with fibroids in premenopausal women	Heavy menstrual bleeding associated with fibroids in premenopausal women; also moderate-to-severe endometriosis pain
Treatment limit	No fibroid-specific limit; follow the product label and clinician's plan	24 months	24 months

What this shows — and what it does not

What it does not show: that menopausal hormone therapy treats fibroids. It does not, and no menopause product is FDA-approved for that purpose.

Elagolix and relugolix are GnRH antagonists. They suppress ovarian hormone production. Estradiol and norethindrone acetate are then added back to reduce bone loss and other low-estrogen effects while the GnRH antagonist treats fibroid-related bleeding. The pharmacology is the opposite of simply adding a menopause dose to an unchanged ovarian hormone supply.

What it does show: the presence of estradiol in a regimen is not enough information to predict what that regimen does to fibroids. Dose, the other drugs in the regimen, ovarian function, treatment purpose, and monitoring all matter.

That is a better question to bring to a clinician than the one you may have been asking. Not "Is estrogen dangerous for me?" — which is too broad to answer. Ask: "What is the full regimen, what is each component doing, and what will make us change course?"

Safety details that matter: Oriahnn and Myfembree are for premenopausal women, carry boxed warnings about thromboembolic disorders and vascular events, and are limited to 24 months because bone loss may not fully reverse. Their labels call for bone-density assessment before treatment and additional monitoring based on risk and duration. Myfembree also warns that women with known or suspected submucosal fibroids may experience fibroid prolapse or expulsion.

Does HRT make fibroids grow?

The evidence is split, and it has been for thirty years. Some trials found growth, several found no meaningful average change, and the 2026 cohort found small early changes that were no longer significant at year five. The studies used different estrogens, routes, progestogens, doses, populations, and measurements, which is why one universal answer has never emerged.

First: what does "growth" mean in these studies?

This trips people up, so let's be clear. Different studies measured different things:

Diameter — how wide a fibroid is, in centimeters or millimeters.
Volume — calculated from three dimensions.
Cross-sectional area — the area of the widest measured slice.
A threshold — for example, the proportion of women whose fibroid increased by more than 25% or 30%.

A change can be statistically significant and still clinically small. A group average can also hide individuals: if some fibroids shrink and others grow, the average can look unchanged.

So when a headline says "HRT grew fibroids," the honest follow-up questions are: grew by how much, measured how, on which regimen, and in whom?

The study ledger

The 2019 systematic review included 17 papers and 1,122 participants. This table shows the key direct studies that most clearly change a real-world HRT decision, plus the 2026 cohort.

Study	Who and how many	Regimen	What happened
Sener 1996, Fertility and Sterility	Randomized; 40 postmenopausal women with small fibroids	Estradiol patch 50 mcg + MPA 5 mg vs oral CEE 0.625 mg + MPA 2.5 mg	Significant growth in the patch/higher-MPA group; no significant change in the oral/lower-MPA group
Frigo 1995, Maturitas	50 perimenopausal women; 12 months	Depot estradiol valerate 4 mg + prasterone at 6–10 week intervals	Fibroid count rose from 2.2 to 3.5 and mean diameter rose from 29.4 to 35.0 mm; the review reports significant increases in both measures
Polatti 2000, Maturitas	224 women overall; 24 months, with a fibroid subgroup	Oral estradiol valerate + cyproterone vs estradiol patch + MPA 10 mg	Fibroid volume changed +4.8% in the oral/cyproterone arm versus +25.5% in the patch/MPA-10 arm
Colacurci 2000, Maturitas	Prospective; 60 postmenopausal women	Estradiol patch + sequential nomegestrol acetate	No significant overall size increase; lower uterine-artery resistance correlated with growth, mainly early in treatment
Palomba 2001, Obstetrics & Gynecology	Prospective nonrandomized study; 70 women with fibroids, plus 35 healthy controls for the bleeding comparison	Estradiol patch + continuous MPA vs calcium carbonate	No significant average increase in fibroid size; early bleeding differences were no longer significant by 12 months
Palomba 2002, European Journal of Obstetrics & Gynecology and Reproductive Biology	Randomized; 27 women	Oral estradiol 2 mg + MPA 2.5 mg vs 5 mg	The higher MPA dose produced more growth; authors recommended the lowest effective progestin dose
Yang 2002, Maturitas	Prospective observational study; 72 postmenopausal women; 3 years	Oral CEE + MPA vs no HRT	Mean volume showed a nonsignificant rise in the first two years and a slight decline in year three; a >25% increase was present in 8.1% of HRT users at year three
Chang 2013, Journal of Menopausal Medicine	38 women; 32 used HRT and 6 did not	Several oral and transdermal estrogen/progestogen regimens	No significant average size change, but 28.1% of HRT users crossed a >30% growth threshold. One short-term subgroup table differed by route, but the overall route comparison was not significant
Moro 2019, Medicina	Review of 17 papers, 1,122 participants; 15 prospective and 9 randomized	Multiple regimens	Conflicting data; fibroids were not an absolute contraindication. The review recommended monitoring and the minimal effective progestin dose
Huang 2026, International Journal of Women's Health	Retrospective cohort; 83 women aged 45–55; up to 5 years	Sequential oral estradiol + dydrogesterone	Minor cross-sectional-area changes in years 1–4 were no longer significant at year 5 and were judged not clinically meaningful

"Just use a patch" does not hold up as a fibroid rule

You have probably read that patches are the safe choice. For fibroids specifically, look at the table again.

Sener's trial found growth in the patch group and not the oral group, but the patch group also received twice the MPA dose. Polatti's larger increase was in the patch/MPA-10 arm. Palomba's 2001 patch study found no significant average increase. Chang reported a short-term route-pattern difference in one tiny subgroup table, but its overall route comparison was not significant. That is not enough for a route rule.

Patches versus pills genuinely matters for other risks, including blood-clot risk. It just has not been shown to be the deciding fibroid variable. Anyone promising that transdermal estrogen is the fibroid-safe route is going further than this evidence goes.

The progestogen question most pages skip

Here is where the small trials point in a direction without settling the matter.

Palomba's 2002 study held the estrogen constant and changed the MPA dose: more MPA, more growth. Polatti's largest increase occurred in the arm with MPA 10 mg. The 2019 review ended with the recommendation to use the minimum effective progestin dose.

That makes progestogen dose one of the clearest regimen signals in a weak and heterogeneous evidence base. It does not prove that progestogens are the only driver, and it does not name a universally safest product.

Turn that into a question, not an action. Ask your prescriber: "Which progestogen am I taking, at what dose, and is that the lowest dose that still protects my uterine lining on this estrogen regimen?"

Do not reduce, skip, or stop a prescribed progestogen on your own. If you still have a uterus and use systemic estrogen, the progestogen is there to protect the endometrium. Removing that protection can increase the risk of endometrial hyperplasia and cancer. This is a prescriber conversation, not a self-adjustment.

What the newest study actually studied

The 2026 study is the one you will see quoted as reassuring. It is reassuring. It is also narrower than the headline.

What it found: 83 women aged 45–55 in the menopause transition used sequential oral estradiol plus dydrogesterone — 1 mg/10 mg or 2 mg/10 mg — and were followed for up to five years. Fibroid cross-sectional area changed slightly in years 1 through 4, but the difference was no longer significant by year 5. Unexpected bleeding occurred in 18.07%, breast discomfort in 10.84%, and gastrointestinal discomfort in 2.41%; most events were described as temporary.

What it excluded:

Submucosal fibroids.
A largest fibroid measuring 5 cm or more.
Women outside the study's 45–55 age range and menopause-transition population.
An untreated comparison group — there was none.

It was retrospective, came from one hospital, and used scans performed by different sonographers. Dydrogesterone is also not an FDA-approved menopause product in the United States.

So here is the sentence you will not find in the headline: if your fibroid is submucosal or 5 cm or larger, the most reassuring recent study did not include you. That does not mean HRT is wrong for you. It means the reassurance was measured on someone else.

If you are already on HRT and worried about a fibroid, the answer is not a panic-stop. It is knowing what needs checking and which care setting can check it. See whether online care fits your situation →

Does HRT double the risk of fibroids after menopause?

The largest population study found that women who had ever used hormone therapy had a little more than twice the rate of hospital admission with surgically confirmed fibroids after menopause. That is a real finding and we are not going to talk you out of it. The same study also shows that the underlying event was uncommon and could not establish what HRT caused.

This is the part of the page we would cut if we were trying to sell you something.

The finding	The number
Relative risk, ever-used HT vs never-used HT	2.33 (95% CI 2.18–2.49)
Study population	610,604 postmenopausal women; mean follow-up 11.4 years
Outcome events	3,561 hospital admissions with surgically confirmed fibroids
Overall five-year incidence across the cohort	0.30% — about 1 in 330
Five-year incidence at age 50–54, all HT histories combined	0.50% — about 1 in 200
Five-year incidence at age 75–79, all HT histories combined	0.11% — about 1 in 900
Obesity vs normal weight	RR 1.46 (1.33–1.59)
Obesity plus ever-used HT vs normal weight and never-used HT	RR 3.30 (2.86–3.79)

Sommer et al., European Journal of Epidemiology, 2015. Do not multiply the 0.50% age-specific rate by 2.33: the 0.50% group already mixes women with different HRT histories.

Three things that ratio does not tell you

One — it does not tell us what changed biologically. The authors could not determine whether hormone therapy led to new fibroids, reduced the normal postmenopausal shrinkage of existing fibroids, or increased the size or symptoms of fibroids already present.

Two — the endpoint was surgery-linked hospital admission. It was not a scan of every woman. One plausible contributor is detection: women using HRT may experience bleeding, receive more investigation, and therefore have fibroids diagnosed. That is an inference, not a measured explanation, and the study design cannot tell us how much of the association it accounts for.

Three — relative and absolute risk answer different questions. A relative risk of 2.33 describes the strength of an association. The age-specific rates show how uncommon the surgery-linked outcome remained. Both matter. Neither predicts your uterus.

A note on body weight, without the lecture. Higher body mass index was associated with higher fibroid admission rates in this study. That does not prove that weight loss will shrink a fibroid or erase HRT-associated risk. It is one risk marker to include in the full conversation, not a moral verdict and not a reason to delay care.

So what do you do with that?

You are not choosing between a risk and zero. You are weighing uncertain fibroid effects against the symptoms you want treated and the other benefits and risks of hormone therapy for your age, timing, route, dose, and health history.

That trade is yours to make with the facts on the table. It is not a stranger's to make for you in eight seconds.

Who needs to pause the HRT decision and get assessed first: anyone with new or unexplained bleeding after menopause, a new pelvic mass, a fibroid that appears to have grown after menopause, or new persistent pelvic pain or pressure. Those findings do not automatically ban HRT. They move the decision out of self-triage and into an examination and diagnostic plan.

Does the type of HRT matter with fibroids?

Yes, but the evidence does not identify one universally safest fibroid regimen. Patch versus pill has not produced a consistent fibroid signal. The progestogen type and dose may matter, but the evidence is small. Systemic hormone therapy and low-dose vaginal estrogen also solve different problems and create different exposure patterns.

Systemic versus low-dose vaginal estrogen

	Systemic menopausal hormone therapy	Low-dose vaginal estrogen
Main problems it treats	Hot flashes, night sweats, and other systemic symptoms; some regimens also prevent bone loss	Genitourinary syndrome of menopause: vaginal dryness, burning, painful sex, and some urinary symptoms
Hormone exposure	Body-wide	Primarily local, with absorption varying by product, dose, formulation, and tissue condition
Progestogen needed?	Yes if you have a uterus, unless your clinician identifies a specific exception	Generally not recommended solely for endometrial protection with standard low-dose vaginal products; unexplained bleeding still needs evaluation
Direct fibroid evidence	Mixed and regimen-specific	Very limited; do not translate "low dose" into "zero possible effect"

The progestogen options — and the US labeling line that matters

If you still have a uterus and use systemic estrogen, you generally need adequate progestogen protection. Not to shrink fibroids — it does not do that — but to protect the uterine lining.

Common or relevant options in this evidence include:

Micronized progesterone — an FDA-approved oral progesterone product is available in the US.
Dydrogesterone — used in the 2026 study, but not FDA-approved in the US.
Medroxyprogesterone acetate (MPA) — the drug carrying the dose signal in the Palomba and Polatti studies.
Norethindrone acetate — the progestogen in Activella and in the add-back component of both Oriahnn and Myfembree.
A 52 mg levonorgestrel intrauterine system, such as Mirena — used in UK menopause practice for endometrial protection, but not FDA-approved in the US for use as the progestogen component of menopausal hormone therapy.

The current US Mirena label approves it for contraception and for heavy menstrual bleeding in people choosing intrauterine contraception. It also lists a uterine anomaly — including fibroids that distort the uterine cavity — as a contraindication. That is the decision point, not a universal fibroid-size cutoff pulled from another country's heavy-bleeding pathway.

Ask: "Does my fibroid distort the cavity enough to make an intrauterine system unsuitable, and if you are using it for HRT protection, are we clear that this is an off-label US use?"

That is a real question. It is better than walking into the appointment with a made-up 3 cm rule.

What changes the answer for you?

Four things move this from a general debate to your decision: where the fibroid sits, how big it is and whether it changed, which progestogen plan you are using, and whether you have bled after menopause. The first three shape the discussion. The fourth can change the urgency and the testing pathway.

Find yourself in this table. It is the most useful thing on the page.

If this is you	What it changes	Where to start
Fibroid under 5 cm, intramural or subserosal, documented on a scan, and no new bleeding or pressure	Closest to the population in the reassuring 2026 study, although that study used one specific oral regimen in women aged 45–55	Online menopause care can be reasonable if the service reviews records and can arrange imaging; bring the report and agree on triggers for reassessment
Submucosal fibroid	Excluded from the 2026 study; it projects into the cavity where bleeding starts, and Myfembree carries a prolapse/expulsion warning in this group	In-person gynecology is the stronger starting point, especially if bleeding or symptoms are active
Largest fibroid 5 cm or more	Outside the 2026 study's criteria	Use an imaging-led, individualized plan; size alone is not an automatic HRT contraindication
Already on HRT with new bleeding, pressure, or pain	A known fibroid does not get to explain a new symptom without assessment	Contact the prescriber; the urgency and tests depend on timing, severity, and risk factors
New or unexplained bleeding after menopause, or bleeding outside an expected cyclic HRT pattern	Moves the problem out of online-first self-triage	Prompt bleeding evaluation
Fibroid appears to have grown after menopause	Needs diagnostic review before the hormone decision continues	In-person assessment and review of prior and current imaging
Fibroids were "mentioned once," but you have no report	Size, location, and change cannot be verified	Retrieve the report or arrange appropriate imaging before relying on a generic answer
Uterus fully removed	Fibroid growth is usually no longer the issue	Estrogen-only may be appropriate; confirm the operation and any exception with the operative report

Three facts to find before you book anything

Your scan report usually has them. Go find it.

The size of the largest fibroid, in centimeters. Do not rely on fruit comparisons or a phrase like "12-week uterus"; that phrase describes the whole uterus, not one fibroid.
The location. Look for submucosal, intramural, subserosal, or pedunculated.
The date of the scan — and an older measurement if one exists. Change over time matters more than one isolated number.

Write those down. You have just turned I have fibroids into information a clinician can use.

If that is your situation, do not choose a provider blind. Find your best-fit care route → Free. About 90 seconds. No email.

Can you use vaginal estrogen if you have fibroids?

Low-dose vaginal estrogen is not listed as contraindicated for fibroids, and it is designed to treat vaginal and urinary symptoms with primarily local exposure. Absorption varies by product and dose. Direct fibroid-specific research is sparse, so "primarily local" should not be rewritten as "zero systemic absorption" or "zero possible fibroid effect."

Set your expectations honestly. If your main problem is dryness, burning, urinary symptoms, or painful sex, low-dose vaginal estrogen is a genuinely separate option worth discussing. If your main problem is hot flashes and broken sleep, vaginal estrogen is not a workaround — it does not treat systemic vasomotor symptoms.

Standard low-dose vaginal estrogen generally does not require a progestogen solely for endometrial protection, but unexplained bleeding still needs evaluation. The 0.01% estradiol cream label in our ledger says systemic absorption may occur and carries the same adverse-reaction line about fibroid enlargement found on several systemic estrogen labels. Product, dose, and formulation matter.

We are not going to tell you vaginal estrogen has zero effect on fibroids, because the direct evidence is not there. What we can tell you is that fibroids alone do not create a label-level locked door.

If someone told you "no estrogen at all" because of your fibroids — including low-dose vaginal estrogen for genitourinary symptoms — ask which finding in your history or scan created that rule. A second opinion can be reasonable when the answer was broad and the reasoning was never explained.

I'm bleeding on HRT. Is it the fibroid?

Maybe — and a known fibroid is not enough to close the case. Unscheduled bleeding is common after starting or changing HRT, but the correct next step depends on whether you are postmenopausal, when the bleeding began, whether it is heavy or prolonged, which regimen you use, and your endometrial-cancer risk factors.

The 2026 fibroid cohort reported unexpected bleeding in about 18% of participants. That number shows bleeding can occur on the studied regimen. It does not tell you why you are bleeding.

What current guidance actually says

The 2026 British Menopause Society guideline starts with a full review of the bleeding pattern, exact HRT preparation, adherence, and individual cancer risk factors, plus an abdominal and pelvic examination where appropriate.

For women at low risk, the guideline allows HRT or progestogen adjustments for up to six months when bleeding begins within six months of starting HRT or persists within three months of a dose or preparation change. It recommends urgent transvaginal ultrasound sooner when bleeding first appears later than those windows, is heavy or prolonged, or occurs with risk factors.

In the United States, ACOG's April 2026 update recommends both transvaginal ultrasound and endometrial tissue sampling for most patients with postmenopausal bleeding, with the final approach shaped by clinical context and shared decision-making.

That is why two true statements can sit together:

Bleeding can be common early in HRT treatment.
Bleeding after menopause still deserves a real assessment rather than an assumption.

Why "it is probably just the fibroid" is the wrong reassurance

Fibroids, polyps, endometrial thickening, cervical or vaginal causes, medication patterns, and endometrial cancer can all enter the differential. A known fibroid gives everyone something convenient to blame. Reassurance that arrives before the history and appropriate evaluation is not reassurance. It is a guess wearing a lab coat.

Do not use stopping HRT as a home diagnostic test

Do not stop, restart, skip, or change your regimen on your own to see what happens. Contact the prescriber and let the bleeding pattern guide a plan.

Depending on timing, severity, risk factors, and your preference, the clinician may continue the regimen while adjusting the progestogen, arrange imaging and sampling, or supervise a pause or stop. The 2026 BMS guidance explicitly includes weaning off HRT as one clinician-supported option for some low-risk women with persistent bleeding. The point is not "never stop." The point is do not improvise the diagnostic pathway alone.

What to write down before you are seen

The date your HRT started or last changed.
The exact product, dose, route, and schedule.
Any doses you missed.
Whether you use continuous-combined or sequential/cyclic HRT.
The first and last day of bleeding.
Spotting versus heavy, prolonged, or painful bleeding.
Any previous scan, biopsy, polyp, fibroid procedure, or hysterectomy.
Your latest cervical screening status, where relevant.

When to stop reading this page and get seen

Four situations need an in-person assessment before a website can resolve the hormone decision: new or unexplained bleeding after menopause, a new or enlarging postmenopausal pelvic mass, new persistent pelvic pain or pressure, and heavy or prolonged bleeding that makes you unwell. These are not reasons to panic. They are reasons not to solve the problem through an intake form.

If any of those describe you, call the clinician who prescribes your HRT, a gynecologist, or an urgent service appropriate to the severity. Seek urgent or emergency care for severe bleeding, fainting, chest pain, shortness of breath, or other acute symptoms.

We would genuinely rather lose you here than have you make a hormone decision around an unanswered diagnostic question.

The rare thing you are probably already worried about

Let's name it, so you are not searching it at 2 a.m.

Uterine leiomyosarcoma is a rare cancer of uterine smooth muscle. A benign fibroid does not turn into leiomyosarcoma. The problem is that a presumed fibroid and a sarcoma can sometimes look similar before surgery, and no preoperative test can reliably exclude leiomyosarcoma in every case.

Rapid growth by itself is not a reliable cancer discriminator. ACOG notes that uterine size or rapid growth has not been associated with increased leiomyosarcoma risk. New growth after menopause, a new mass, or postmenopausal bleeding still warrants assessment — not because speed proves cancer, but because the finding needs an explanation.

That is the honest shape of it. We are not going to hand you survival statistics when the useful next step is an appointment.

If hot flashes are making your life unbearable while you are being worked up, FDA-approved nonhormonal options can be discussed in parallel. See our nonhormonal options for hot flashes page.

Can you take HRT after myomectomy, embolization, ablation, or hysterectomy?

It depends on which procedure you had and what anatomy remains. A total hysterectomy usually closes the fibroid question and removes the need for endometrial protection. Myomectomy, uterine artery embolization, and endometrial ablation leave the uterus in place, so the progestogen and bleeding conversation continues.

Procedure	Is the uterus still present?	What remains relevant?	What changes for HRT
Total hysterectomy	No	Confirm the operative details and any separate reason a clinician may still recommend a progestogen	Estrogen-only therapy is usually an option
Hysterectomy plus both ovaries removed	No	Surgical menopause can begin abruptly if you were not already menopausal	Estrogen-only may be considered; age, timing, symptoms, and health history shape the plan
Myomectomy	Yes	Fibroids were removed, but new fibroids or recurrence can occur	Adequate progestogen protection is still needed with systemic estrogen
Uterine fibroid/artery embolization (UFE/UAE)	Yes	The fibroid remains in place while its blood supply is reduced	Adequate progestogen protection is still needed with systemic estrogen; follow the post-procedure imaging plan
Endometrial ablation	Yes	The uterus remains, and residual endometrium may remain	Combined HRT is generally used with systemic estrogen; it may be sequential or continuous
Subtotal/supracervical hysterectomy	Cervix remains	Residual endometrium may or may not remain	The need for a progestogen may be uncertain; records or a supervised challenge can clarify it

The one people get wrong: subtotal hysterectomy

After a subtotal or supracervical hysterectomy, the cervix stays. The practical problem is that the operative record may not clearly establish whether functional endometrium remains. That determines whether unopposed systemic estrogen is appropriate.

Current British Menopause Society guidance describes a supervised approach when the records do not settle it: use sequential combined HRT for up to three months as a progestogen challenge. If no bleeding occurs, estrogen-only therapy may then be considered. That is UK clinical guidance, not an FDA-labeled test, and it belongs under clinician supervision.

That is a real protocol, not a shrug.

In every procedure above: retrieve the operative report. "I had a hysterectomy years ago" is not enough detail for this decision, and an online intake form cannot reconstruct anatomy that is missing from the record.

Do you need an ultrasound before starting HRT with fibroids?

There is no universal scan requirement or evidence-based calendar that applies to every woman with fibroids starting HRT. The sensible plan depends on whether the diagnosis is confirmed, how recent the scan is, fibroid size and location, symptoms, postmenopausal status, and whether anything has changed.

We are saying this plainly because fixed schedules such as "every six months" or "every year" are often repeated as if they were universal standards. The 2019 review recommended periodic examination and monitoring, but it did not establish one interval for everyone.

What is reasonable to ask for:

A baseline report you can retrieve if the diagnosis, size, or location is uncertain.
Comparison with an older study when growth is the concern.
An agreed trigger for reassessment — new bleeding, persistent pressure or pain, a palpable change, or another finding your clinician identifies.
Clarity on who orders the imaging, who receives the result, and who changes the plan. This is where a telehealth plan can fail if nobody owns escalation.

One research finding is worth keeping as context rather than turning into a consumer rule: Colacurci's study found that lower uterine-artery resistance on Doppler ultrasound correlated with which fibroids grew during HRT. It has not become a standard prediction test. It is a clue, not a booking instruction.

Can online HRT care handle fibroids, or should you see someone in person?

Online menopause care can be a reasonable starting point for a stable, documented fibroid history when the service can review records, order or coordinate imaging, and respond to bleeding. It is not the right first stop for a new mass, unexplained postmenopausal bleeding, severe symptoms, or an unconfirmed diagnosis that requires an examination.

The question is not online versus in person. It is whether the care model can escalate when the answer stops being online.

What we verified about three online options

Checked August 6, 2026 against each provider's own published pages. Prices and policies can change; confirm during intake or checkout.

Provider	Care model	Fibroid-relevant escalation	Published price and payment	Medication/FDA-status boundary	Material limit
Midi Health	Video visits with a clinician; available nationwide	Says clinicians can order bloodwork or imaging and send patients to local labs and imaging centers	Self-pay: $250 initial visit, $150 continued-care visit. In-network with most PPO plans; plan costs vary	Prescriptions depend on clinician assessment and the exact product chosen	Midi says it cannot treat Medicaid or Medi-Cal patients even as self-pay; it is not a substitute for an urgent pelvic exam
Sesame	$59/month menopause video-care subscription with provider choice, video visits, and messaging	Basic listed lab work is included if ordered; the program does not publish an included pelvic-ultrasound pathway	Cash-pay subscription; medication costs are separate. Sesame does not bill insurance for the subscription	The page lists FDA-approved prescription options and says compounded products are not shown to be safer or more effective; exact prescription depends on the clinician	Severe or complex cases may require in-person evaluation; no refund for the first month after the initial visit has occurred
Winona	Questionnaire and secure messaging; no video call required	No public imaging pathway found on the pages we checked	Estradiol patch advertised from $149/month; no direct insurance billing; HSA/FSA may be used	Published pages conflict: product pages call patches, tablets, and progesterone capsules FDA-approved, while an October 2025 help-center article says Winona's treatments are not FDA-approved because they are prepared through its 503A pharmacies	Available only in listed states and Puerto Rico and only for HRT ages 35–59; confirm the exact manufacturer, NDC, dispensing pharmacy, and whether the dispensed product is FDA-approved before paying

We may earn a commission if you start care through some links below. It does not change the facts, the care-setting decision, or who we exclude. Read the affiliate disclosure.

Which one fits a stable fibroid history best?

If you have a documented, stable fibroid, no new bleeding, and want to start with video care: Midi is the strongest online-first fit of these three for one specific reason. Its own site publishes a pathway for ordering imaging and sending patients to local imaging centers. On a fibroid page, that sentence matters more than a low subscription price.

Midi does not treat Medicaid or Medi-Cal patients, even as self-pay. If that is your coverage, Midi is not your route. A local gynecology service, your health plan's network, or a cash-pay option that can coordinate in-person assessment is the better starting point.

If the stable, documented scenario fits you: Check insurance and availability with Midi →

Where Sesame fits — and where it does not

If cash-pay pricing and ongoing video access matter: Sesame publishes the clearest low monthly care price here at $59, with video visits, messaging, and a defined set of basic labs when ordered. Medication is separate.

But the menopause subscription does not publish an included pelvic-ultrasound pathway, and video care cannot perform a pelvic examination. If you have postmenopausal bleeding, a new mass, or an uncertain diagnosis, do not use the subscription price as a reason to skip in-person evaluation.

If you need cash-pay menopause video care after the fibroid question is already documented: See Sesame's current menopause program →

Why Winona is not the clean FDA-approved choice on this page

Winona's live pages make contradictory FDA-status claims. Its estradiol patch, estradiol tablet, and progesterone capsule pages say those products are FDA-approved. Its help center says Winona's treatments are not FDA-approved because they are produced through its 503A compounding pharmacies. Both statements cannot describe the same dispensed product in the same way.

That does not prove every Winona prescription is compounded. It does mean the website does not give a reader enough consistent information to assume an advertised patch is the FDA-approved finished product. Ask for the exact manufacturer, NDC, strength, dispensing pharmacy, and whether the final dispensed product — not merely an ingredient — is FDA-approved.

For a reader with a fibroid history who may need imaging escalation, the unresolved product-status language and the lack of a published imaging route make Winona a weaker starting point than Midi. We would rather tell you that than turn an informational page into a three-button sales page.

What should you bring, and what should you ask?

Bring the documents that turn a broad fear into a specific decision: your scan report, operative report if you had a procedure, medication list, and bleeding timeline. Ask what needs evaluating first, which progestogen plan is being proposed, and what finding would trigger imaging or a change in treatment.

Records checklist

[ ] Most recent pelvic ultrasound or MRI report — plus an older report if it shows change over time
[ ] Largest fibroid size in centimeters and its location
[ ] Date of each scan
[ ] Operative report from any myomectomy, embolization, ablation, or hysterectomy
[ ] Whether the uterus, cervix, and ovaries were removed
[ ] Current medications and supplements
[ ] Exact HRT product, dose, route, schedule, and start or change date, if you are already taking it
[ ] Bleeding timeline
[ ] Pressure, pain, urinary, or bowel-symptom timeline
[ ] Your main treatment goal — hot flashes, sleep, vaginal symptoms, bone protection, or a combination

Ten questions worth asking

Does my bleeding pattern need evaluating before we start or change hormone therapy?
Is my last scan recent and detailed enough for this decision?
Where is the fibroid, how large is it, and has it changed?
Which progestogen are you recommending, at what dose, and why that one?
Is that the lowest progestogen dose that still adequately protects my endometrium on this estrogen regimen?
Does my fibroid distort the uterine cavity enough to make a 52 mg levonorgestrel IUD unsuitable?
Is each medication an FDA-approved finished product or a compounded prescription? What manufacturer, NDC, and pharmacy will dispense it?
What would count as a meaningful change in bleeding, pressure, pain, or imaging?
Who orders and reads the imaging if something changes?
When are we reassessing this plan, and who books that follow-up?

What can the evidence still not tell you?

Current research cannot name one universally safest HRT regimen for women with fibroids, and it cannot predict how an individual fibroid will respond. The gaps are largest exactly where the anxiety is highest: submucosal fibroids, fibroids 5 cm or larger, women with substantial symptoms, postmenopausal growth, and low-dose vaginal estrogen.

What the evidence supports:

Fibroids are not an automatic barrier to menopausal hormone therapy.
Some regimens were associated with growth in some studies.
Other regimens produced little or no meaningful average change.
Progestogen dose is one of the clearest repeated regimen signals, but the evidence is too small to declare it the only driver.
Bleeding, symptoms, fibroid location, change over time, and diagnostic certainty can matter more than a generic patch-versus-pill rule.
A stable documented fibroid and an unexplained postmenopausal bleed are not the same telehealth problem.

What the evidence does not support — and what we will not claim:

"HRT never grows fibroids."
"Patches are the safest HRT option for fibroids."
"Micronized progesterone prevents fibroid growth."
"Low-dose vaginal estrogen cannot affect fibroids."
"Every woman with fibroids needs an ultrasound every six months."
"The 2026 study proves HRT is safe for all women with fibroids."
"Rapid fibroid growth proves cancer."
"A compounded hormone is equivalent to an FDA-approved finished product because an ingredient is FDA-approved."

Anyone stating those with confidence has gone further than the research. Including us, if we ever do.

How did The HRT Index research this page?

We read current US prescribing information, separated label facts from study findings, and assembled the regimen details and limits that single consumer pages usually leave apart. This is editorial research, not medical advice, and it has not been medically reviewed by a clinician. We say that because it is true, not as a decorative disclaimer.

Our review framework is The HRT Index Verification Standard: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, the full roster quarterly. We evaluate providers on five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, access.

What we actually verified

August 6, 2026

Read the current DailyMed records for Activella, generic oral estradiol tablets, Vivelle-Dot, CombiPatch, Delestrogen, and estradiol vaginal cream 0.01%, and checked where fibroids appear relative to contraindications and adverse reactions.
Confirmed the February 12, 2026 FDA announcement approving boxed-warning changes for an initial group of menopausal hormone products.
Confirmed the components, indications, 24-month limits, bone-loss language, and thromboembolic boxed warnings in the Oriahnn and Myfembree labels.
Read the 2019 review of 17 papers and 1,122 participants, then checked the key direct trials by regimen rather than treating HRT as one exposure.
Read the 2026 estradiol/dydrogesterone cohort, including the exclusion of submucosal fibroids and fibroids measuring 5 cm or more.
Read the Million Women Study fibroid analysis, including its absolute event rates and the authors' causal limits.
Read the March 2026 Women's Health Concern fibroid factsheet, the 2026 British Menopause Society unscheduled-bleeding guideline, the April 2026 ACOG postmenopausal-bleeding update, and current BMS progestogen guidance.
Checked current published pricing, payment terms, escalation claims, FDA-status language, and material limits on Midi, Sesame, and Winona.

What we did not verify — and will not claim

We have not taken, prescribed, dispensed, or tested any HRT product.
We did not review your ultrasound and cannot diagnose a fibroid or decide whether HRT is appropriate for you.
We did not establish a universal scanning schedule, because current evidence does not provide one.
We did not identify one best estrogen route or progestogen for every woman with fibroids, because the evidence does not support one.
We do not turn the Million Women Study's age-specific 0.50% rate into a personal HRT risk by multiplying it by 2.33; that arithmetic would misuse the study groups.
We did not treat a provider's claim that an ingredient is FDA-approved as proof that a compounded finished product is FDA-approved.
We did not publish a customer testimonial to imply that one woman's response predicts yours.

Frequently asked questions about HRT and fibroids

Are fibroids a contraindication to HRT? No. Fibroids were not listed under Contraindications in the six current US menopause-hormone labels we reviewed, and March 2026 clinical guidance says fibroids are not a contraindication to receiving or continuing HRT. Bleeding, symptoms, fibroid size and location, change over time, and your wider health history still shape the decision.

Does HRT make fibroids grow? Sometimes, on some regimens, in some studies. The 2019 review found conflicting results across 17 papers. Some trials showed growth, others showed no meaningful average change, and the 2026 cohort found minor early changes that were no longer significant by year five. The evidence cannot predict one fibroid's response.

Does HRT cause new fibroids after menopause? The largest cohort found a higher rate of surgically confirmed fibroid admissions among women who had ever used HT, but it could not determine whether HT caused new fibroids, reduced normal postmenopausal shrinkage, or affected fibroids that were already present. It also measured surgery-linked admissions, not ultrasound findings in every participant.

Which HRT is best if you have fibroids? There is no universally best regimen. A useful consultation focuses on the symptom being treated, whether you have a uterus, the fibroid's location and change over time, the estrogen route and dose, and the exact progestogen plan. Do not change the progestogen on your own.

Is the patch safer than the pill for fibroids? Not according to the fibroid evidence. Patch and oral studies produced mixed findings, and some comparisons also changed the progestogen dose, making route impossible to isolate. Transdermal estrogen can have advantages for blood-clot risk; that is a different question from fibroid growth.

Do fibroids shrink after menopause? Most tend to shrink as ovarian hormone production falls, but not all disappear. HRT may make the expected reduction smaller. In the Million Women Study, the five-year rate of surgically confirmed fibroids was about 0.50% at ages 50–54 and fell with age.

Is bleeding on HRT with fibroids normal? Unscheduled bleeding can be common after starting or changing HRT, but "common" is not a diagnosis. Timing, severity, regimen, adherence, and cancer-risk factors determine whether the next step is adjustment, urgent ultrasound, endometrial sampling, or another evaluation. New or unexplained postmenopausal bleeding should not be blamed on a fibroid without assessment.

Can you use vaginal estrogen with fibroids? Fibroids are not listed as a contraindication in the vaginal estradiol cream label we reviewed. Low-dose vaginal products are designed for primarily local treatment, but absorption varies and direct fibroid-specific research is limited. They treat vaginal and urinary symptoms, not hot flashes or night sweats.

Should I stop HRT if a fibroid grows? Do not make that change alone. Growth after menopause needs review of the imaging, symptoms, and regimen. The 2019 review recommended monitoring and discontinuation if fibroids increase, but the real decision belongs with the clinician who can confirm the change and assess the alternatives.

Can I take HRT after a myomectomy or embolization? The conversation usually continues because the uterus remains. With systemic estrogen, adequate progestogen protection is still generally needed, and fibroids may recur or remain after the procedure. Bring the operative report and follow-up imaging plan.

Do I still need progesterone after a hysterectomy for fibroids? After a total hysterectomy, a progestogen is usually unnecessary with systemic estrogen, although individual exceptions exist. After a subtotal or supracervical hysterectomy, residual endometrium may remain, so records or a supervised progestogen challenge may be needed.

Do I need an ultrasound before starting HRT with fibroids? There is no universal requirement or fixed interval. A retrievable baseline is useful when the diagnosis, size, location, or change is uncertain. An agreed plan for what triggers re-imaging is more defensible than a made-up every-six-month rule.

Could a growing fibroid be cancer? Leiomyosarcoma is rare, and benign fibroids do not transform into it. No preoperative test rules it out perfectly, but rapid growth alone is not a reliable cancer marker. A new or enlarging postmenopausal mass, postmenopausal bleeding, or persistent symptoms still warrants prompt assessment.

Can an online menopause clinic handle fibroids? It can be a reasonable starting point for a stable, documented fibroid if the service can review records and arrange imaging or referral. A new mass, unexplained postmenopausal bleeding, severe symptoms, or an unconfirmed diagnosis belongs in person first.

Still not sure which HRT program fits? Take the free 90-second matching quiz.

You now have the core evidence. The last step is matching it to the care setting that can actually handle your situation.

Find My HRT Path → — answer a few questions and get your best-fit online-care route, why it fits, two backup paths, and a clear flag when online care is not the right starting point. No email required.

Sources

Clinical guidance and regulatory sources

Women's Health Concern / British Menopause Society. Fibroids factsheet, March 2026.
British Menopause Society. Management of unscheduled bleeding on hormone replacement therapy, updated 2026.
American College of Obstetricians and Gynecologists. Updated guidance on evaluation of postmenopausal bleeding, April 2026.
British Menopause Society. Progestogens and endometrial protection, May 2026.
American College of Obstetricians and Gynecologists. Uterine morcellation for presumed leiomyomas, Committee Opinion No. 822.
The North American Menopause Society. Genitourinary syndrome of menopause position statement, 2020.
FDA. FDA approves labeling changes to menopausal hormone therapy products, February 12, 2026.
FDA. Human drug compounding: questions and answers.

US prescribing information checked August 6, 2026

DailyMed. Activella — estradiol/norethindrone acetate tablets.
DailyMed. Estradiol tablets — current generic record.
DailyMed. Vivelle-Dot — estradiol transdermal system.
DailyMed. CombiPatch — estradiol/norethindrone acetate transdermal system.
DailyMed. Delestrogen — estradiol valerate injection.
DailyMed. Estradiol vaginal cream 0.01% — current generic record.
DailyMed. Oriahnn — elagolix/estradiol/norethindrone acetate and elagolix.
DailyMed. Myfembree — relugolix/estradiol/norethindrone acetate.
DailyMed. Mirena — levonorgestrel intrauterine device.

Fibroid and HRT studies

Moro E, et al. The impact of hormonal replacement treatment in postmenopausal women with uterine fibroids: a state-of-the-art review. Medicina. 2019;55(9):549.
Huang M, et al. Effects of menopausal hormone therapy on uterine fibroids in women during menopausal transition. International Journal of Women's Health. 2026;18. doi:10.2147/IJWH.S615332.
Sommer EM, et al. Uterine fibroids in postmenopausal women and associations with hormone therapy and body mass index. European Journal of Epidemiology. 2015;30(6):493–499.
Sener AB, et al. Fertility and Sterility. 1996;65:354–357.
Frigo P, et al. Maturitas. 1995;21:221–225.
Polatti F, et al. Maturitas. 2000;37:27–32.
Colacurci N, et al. Maturitas. 2000;35:167–173.
Palomba S, et al. Obstetrics & Gynecology. 2001;98:1053–1058.
Palomba S, et al. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2002;102:199–201.
Yang CH, et al. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women — a 3-year study. Maturitas. 2002.
Chang IJ, et al. Effects of menopausal hormone therapy on uterine myoma in menopausal women. Journal of Menopausal Medicine. 2013;19(3):123–129.

Provider facts checked August 6, 2026

Midi Health. How Midi works and pricing and insurance.
Sesame. Menopause treatment program.
Winona. Estradiol patch, FDA-status help-center article, state availability, and FAQ.

Match the care setting to the unanswered question.

If your fibroid history is stable and documented, the source identifies Midi's published imaging-escalation pathway as the strongest online-first fit. If you need cash-pay video care after the fibroid question is documented, review Sesame's current program. New or unexplained postmenopausal bleeding belongs with in-person care first. Use Find My HRT Path only for the broader online-care decision.

Keep reading: